Annual report pursuant to Section 13 and 15(d)

Sponsored Research and Clinical Trial Agreements - Additional Information (Details)

v3.20.1
Sponsored Research and Clinical Trial Agreements - Additional Information (Details) - USD ($)
1 Months Ended 12 Months Ended
Mar. 12, 2018
Mar. 12, 2018
Jan. 03, 2018
Nov. 30, 2017
Nov. 28, 2017
Jul. 03, 2017
Feb. 17, 2017
Mar. 31, 2015
Dec. 31, 2019
Jun. 30, 2017
Feb. 17, 2017
Dec. 31, 2019
Dec. 31, 2018
Oct. 31, 2016
Research and Development Expense                       $ 81,326,000 $ 87,383,000  
Sponsor Research Agreement Funding Commitment     $ 900,000 $ 2,300,000                    
Research and Development Expense (Excluding Acquired in Process Cost)                       75,236,000 83,333,000  
Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross $ 100,000                          
Payment of Upfront Fees                       1,000,000    
Revenue Recognition Milestone Method Payments Due                       14,500,000    
Research and Development Arrangement, Contract to Perform for Others, Description and Terms     2 years                      
Umass Sponsored Research Agreement [Member]                            
Research and Development Expense                       800,000    
Payments For Research And Development Expenses                       800,000    
Sponsor Research Agreement Funding Commitment                 $ 0     0 800,000  
UPenn Sponsored Research Agreement [Member]                            
Research and Development Expense                       2,000,000    
Payments For Research And Development Expenses                       300,000    
Sponsor Research Agreement Funding Commitment                 1,100,000     1,100,000 500,000  
Sponsored Research Agreement [Member]                            
Research and Development Expense (Excluding Acquired in Process Cost)                       100,000 0  
Checkpoint [Member]                            
Reimbursement Of Cost Recognized As Revenue                       0 35,000  
AR CD123 License [Member]                            
Revenue Recognition Milestone Method Payments Due Over Three Years             $ 200,000              
Caelum [Member]                            
Payments For Research And Development Expenses                       100,000    
Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross   $ 100,000                        
Cellvation [Member]                            
Research and Development Expense                         300,000  
Payments For Research And Development Expenses                       100,000    
Research And Development Expense Payable Milestone Payment                           $ 800,000
Helocyte Inc [Member]                            
Payments For Research And Development Expenses                       0 100,000  
Payment of Upfront                   $ 1,500,000        
Pentamer [Member]                            
Payments For Research And Development Expenses                       0 1,300,000  
City of Hope (COH) [Member]                            
Research and Development Expense                       500,000 500,000  
City of Hope (COH) [Member] | AR CD123 License [Member]                            
Research and Development Expense                       1,200,000 800,000  
Payment of Upfront Fees             20,000              
Revenue Recognition Milestone Method Payments Due             100,000              
Mustang [Member]                            
Research and Development Expense                       2,000,000 2,000,000  
Mustang [Member] | COH [Member]                            
Amount payable for research               $ 2,000,000            
Mustang Bio, Inc [Member]                            
Research and Development Expense                       800,000 1,300,000  
Research And Development Expense Payable Milestone Payment             200,000       $ 200,000      
Payment of Upfront Fees             $ 9,300              
Revenue Recognition Milestone Method Payments Due                     $ 100,000      
Mustang Bio, Inc [Member] | AR IL-13 License [Member]                            
Research and Development Expense                       900,000 1,100,000  
Mustang Bio, Inc [Member] | CD20 Technology License [Member]                            
Payment of Upfront Fees           $ 5,300,000                
Mustang Bio, Inc [Member] | Beth Israel Deaconess Medical Center - CRISPR (multiple programs)[Member]                            
Research and Development Expense                       100,000 100,000  
Payment of Upfront Fees         $ 800,000                  
Mustang Bio, Inc [Member] | S Agreement with St. Jude                            
Research and Development Expense                       800,000    
Payment of Upfront Fees                 $ 800,000          
Tamid [Member]                            
Research and Development Expense                       $ 0 $ 700,000  
Research and development payments due       $ 800,000